Medicare to cover obesity drugs, but not for weight loss

Source

Medicare to cover obesity drugs, but not for weight loss

“CMS has issued guidance to Medicare Part D plans stating that anti-obesity medications (AOMs) that receive FDA approval for an additional medically accepted indication can be considered a Part D drug for that specific use,” the spokesperson added, specifying that drugs that are FDA-approved for only weight loss do not fall under this consideration.

Wegovy, Rybelsus, and Ozempic, are the different brand names for Semaglutide. They have a black box warning for Medullary thyroid cancer.* 🤦🏼‍♀️

Related:

Wegovy side effects: What you should know

*Obesity and Cancer

Progressives Say Congress Must Raise Debt Limit Now to Protect Social Programs

Progressives Say Congress Must Raise Debt Limit Now to Protect Social Programs

The programs have long been targets of Republicans, despite the fact that Social Security is fully funded through 2035 and is able to pay for 90% of benefits for the next 25 years, even without Congress acting to expand it.

Related:

GOP’s Thune Sees Debt-Ceiling Hike as Vehicle for Budget Cuts

White House Knocks Thune’s Bid to Tie Debt Limit to Entitlements

‘There’s no way that patients are going to be able to afford that.’ Why aren’t new drugs that can help you lose weight more widely used?

A pair of new drugs offer something many Americans desperately want: a way to lose weight.

‘There’s no way that patients are going to be able to afford that.’ Why aren’t new drugs that can help you lose weight more widely used?

“Ten years ago, policymakers would come out and say, ‘Fat people need to eat less and move more.’” – majority of people still feel this way, unfortunately. Most of them don’t know how hard it is to lose weight or if they have, they don’t understand that one weight loss plan may not work for another. Same way it is with medical treatments. One size fits all doesn’t fit all!

Prescription Drug Price Reforms Won’t Happen for Years

Prescription Drug Price Reforms Won’t Happen for Years

The two biggest benefits for seniors in the IRA are the Medicare negotiation of certain high-cost prescription drugs, and the $2,000 out-of-pocket cap. But while price negotiations technically start next year, no consumer will see the benefit until the new prices begin in 2026, and even then on only 10 drugs (another 15 are added in 2027 and 2028, rising to 20 by 2029 and subsequent years).

The $2,000 out-of-pocket cap, which is across the board for all seniors, not just on certain drugs, is even worse. That cap doesn’t go into effect until 2025, although out-of-pocket costs get capped at $4,000 in 2024. If there is kind of an explanation for delays in setting up Medicare drug price negotiation, for the out-of-pocket cap there is not. You literally tally up patient out-of-pocket costs, which are fully transparent, until they hit $2,000, and then stop them. Why does this take more than two years to pull off? Medicare itself, the entire program, took only a year to implement.

Other parts of the bill do come online more quickly. The insulin price cap of $35 a month for Medicare recipients starts in 2023, as does free vaccine coverage in Medicare and the rebates on Medicare drugs with price increases above inflation. But the inflation rebate is benchmarked to 2021 prices, locking in those high costs, and just would mute price growth. The real benefits here are Medicare negotiations that lower drug prices, and the cap on all prescription drug costs for seniors. Those are delayed.

It is absolutely insane for a political party to boast that it lowered prices for seniors when the price reductions are years and years down the road. That kind of de facto bait and switch leads to distrust and anger. You’d have thought Democrats would have learned this lesson in the Affordable Care Act, whose major benefits didn’t kick in for four years after passage, a time lag that helped lead to two midterm wipeouts. But here we are again, as Democratic officials tout a drug price reform that isn’t visible to anyone.

That’s not necessarily Democrats’ fault (although they could have ignored the parliamentarian, of course). What is their fault is the failure to immediately make evident the benefits of the policy. Democrats have had a tendency to break faith with their base, to make promises and fail to deliver. Here’s a policy they’ve been promising for nearly two decades, they pass the policy, and they’re going to spend years explaining how the implementation is just around the corner. It comes off as double-talk and toxifies a political brand. And in this case, it was unnecessary.

Read More »

Will you get insulin-cost relief from the inflation bill? Not if you have private insurance

Will you get insulin-cost relief from the inflation bill? Not if you have private insurance

But an out-of-pocket cap identical to that for Medicare was stripped from the bill for those with private insurance because Democrats are trying to pass the bill by a simple majority through the reconciliation process. That requires Senate Parliamentarian Elizabeth MacDonough to vet the provisions. She said most of the health-related features were fine, but the insulin proposal for those who have private insurance, not Medicare, violated the Byrd provision, which says that issues “extraneous to the federal budget” cannot be passed by simple majority through reconciliation.

Out-of-pocket spending for those with Part D Medicare drug coverage will be capped at $2,000 a year.

In 2024, a 5% coinsurance payment that now kicks in after someone reaches the catastrophic drug spending level of $7,050 in Medicare will end. Because drug companies set their own prices, 5% on expensive drugs can be a lot of money.

Related:

Read More »

Manchin’s Climate Reversal Comes With Major Caveat: Expanding Oil and Gas

Conservative coal baron Sen. Joe Manchin (D-West Virginia) announced on Wednesday that he has come to an agreement with Democratic leaders for a reconciliation bill with key climate, prescription drug price and tax reforms — with a major caveat to expand oil and gas exploration.

Manchin’s Climate Reversal Comes With Major Caveat: Expanding Oil and Gas

Related:

Senate Dems reach draft deal to extend ACA premiums, lower drug costs

Also included in the Inflation Reduction Act — a bid to lower drug prices. Medicare will be allowed to negotiate the prices of some 10 pharmaceutical drugs in 2026, 15 more drugs in 2027 and 2028 and 20 more in 2029. In addition to price negotiation, the bill also imposes penalizing rebates on pharmaceutical manufacturers who hike drug costs above the rate of inflation starting next year.